TBC1D14 Inhibitors
TBC1D14 inhibitors belong to a specialized class of chemical compounds that target the TBC1 domain family member 14, a protein known to be involved in various cellular processes. The TBC1D14 protein is a GTPase-activating protein (GAP) for Rab GTPases, which are small G proteins that regulate intracellular membrane traffic. The primary function of TBC1D14 is to modulate the activity of these Rab GTPases, thus influencing the trafficking pathways within the cell, such as endocytosis and autophagy. Inhibitors of TBC1D14 are designed to bind to this protein and modulate its activity. By doing so, they can alter the normal functioning of the cellular trafficking machinery. The design of these inhibitors is based on the understanding of the protein's structure and its active sites where it interacts with Rab GTPases. The challenge in developing TBC1D14 inhibitors lies in achieving specificity and potency, ensuring that they effectively target TBC1D14 without off-target effects on other proteins.
The development of TBC1D14 inhibitors is a complex process that involves the synthesis of molecules capable of engaging with the TBC1D14 protein in a manner that affects its regulatory role on Rab GTPases. These inhibitors may work by mimicking the structure of the protein's substrates or by binding to allosteric sites that can induce conformational changes in the protein, thus affecting its activity. The specificity of these inhibitors is crucial, as the TBC1D14 protein is part of a larger family of proteins with similar structures and functions. Detailed biochemical and biophysical assays are employed to characterize the interaction between these inhibitors and the TBC1D14 protein, as well as to understand the molecular basis of their inhibitory action. Advanced techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and computational modeling are often used to elucidate the binding mode of these compounds and to guide the optimization of their inhibitory properties.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). TBC1D14 has been shown to be regulated by nutrients and growth factors, likely through a PI3K-dependent pathway. Inhibition of PI3K by Wortmannin could thus indirectly inhibit TBC1D14 by disrupting upstream signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, functioning similarly to Wortmannin. By blocking PI3K activity, LY294002 indirectly decreases the signaling that may be necessary for TBC1D14 function in response to growth factors or nutrient availability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTOR pathway, which is involved in cell growth and autophagy. Since TBC1D14 has been implicated in autophagy regulation, inhibiting mTOR with Rapamycin could indirectly reduce TBC1D14 activity in autophagy-related processes. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 promotes the degradation of PI3K by inhibiting ubiquitin-specific peptidases USP10 and USP13. This would decrease PI3K levels, potentially reducing the activity of TBC1D14 by limiting the signaling pathways that regulate its function. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine is a class III PI3K inhibitor that impairs the initiation of autophagy. As TBC1D14 is connected to autophagy regulation, the inhibition of autophagy initiation by 3-Methyladenine could indirectly decrease TBC1D14 activity. | ||||||
GSK 2334470 | 1227911-45-6 | sc-364501 sc-364501A | 10 mg 50 mg | $199.00 $1165.00 | 1 | |
GSK2334470 is a selective PDK1 inhibitor that blocks AGC kinase family activation, including AKT. Since AKT is downstream of PI3K and can influence autophagy, inhibiting PDK1 might indirectly affect TBC1D14 function related to autophagy through decreased AKT signaling. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671 is a selective inhibitor of the S6 kinase p70S6K, downstream of mTOR. By inhibiting p70S6K, this compound could indirectly influence the role of TBC1D14 in autophagy by altering the mTOR signaling cascade that regulates this process. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent and selective mTOR inhibitor that acts on both mTORC1 and mTORC2 complexes. Given the involvement of TBC1D14 in autophagy, which is regulated by mTOR, Torin 1 could indirectly reduce TBC1D14's functional activity by disrupting mTOR signaling. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is an inhibitor of vacuolar type H+-ATPase (V-ATPase). It prevents the fusion of autophagosomes with lysosomes, a step in autophagy where TBC1D14 might be involved. This compound could therefore indirectly inhibit TBC1D14 activity by blocking later stages of autophagy. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an autophagy inhibitor that raises the pH within lysosomes, impairing their function. Since TBC1D14 is thought to be involved in autophagy, the use of Chloroquine could indirectly inhibit TBC1D14 by disrupting lysosomal degradation. | ||||||